Document is current
Any future updates will be listed below
-
Authors
Auner, Holger W. https://orcid.org/0000-0003-4040-0642
Brown, Sarah R. https://orcid.org/0000-0002-7975-7537
Walker, Katrina
Kendall, Jessica
Dawkins, Bryony
Meads, David
Morgan, Gareth J.
Kaiser, Martin F. https://orcid.org/0000-0002-3677-4804
Cook, Mark
Roberts, Sadie
Parrish, Christopher
Cook, Gordon https://orcid.org/0000-0003-1717-0412
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited | Takeda Oncology
Myeloma UK
- License Information
-
More Information
Article History
Received: 1 October 2021
Revised: 5 January 2022
Accepted: 24 January 2022
First Online: 1 April 2022
Competing interests
: HWA reports grants from Myeloma UK, during the conduct of the study; grants from Amgen, personal fees from Amgen, personal fees from Karyopharm, personal fees from Takeda, personal fees from Novartis, personal fees from Janssen, outside the submitted work; MK reports Abbvie: Consultancy; Amgen: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Research Support, Travel Support; Janssen: Consultancy, Honoraria, Travel Support; GSK: Consultancy; Karyopharm: Consultancy; Pfizer: Consultancy; Seattle Genetics: Consultancy; Takeda: Consultancy, Honoraria, Travel Support; GM reports other from AbbVie, other from Amgen, other from Celgene, other from Janssen, other from Oncopeptide, other from Roche, other from Takeda, outside the submitted work; CP reports Speaker Bureau Fees, Conference Registration Support and Professional Development Support from Takeda; SRB reports grants from Myeloma UK; MC declares honoraria and travel fees from Janssen, Celgene, Takeda, Amgen and Chugai, has received research support from Celgene, CRUK and Janssen, and is now an employee of BMS. GC declares research funding from Takeda, BMS, IQVIA, and consultancy for Takeda, Amgen, BMS, Janssen, Karyopharm, Oncopeptides, Sanofi, Roche, Pfizer, IQVIA. KW, JK, BD, DM, SR have nothing to disclose.
